GEN Exclusives

More »

GEN News Highlights

More »
Oct 24, 2011

WuXi Acquires Chinese Clinical CROs MedKey and Jiecheng

  • WuXi Pharmaceuticals has bought two related Shanghai-based contract clinical research development services, MedKey Med-Tech Development and Jiecheng Med-Tech Development. Founded in 2006, the two acquired firms provide services spanning regulatory affairs, Phase I–IV clinical trials management, and clinical trial site management, throughout most of China.

    “This acquisition provides WuXi an existing clinical development service capability and infrastructure that WuXi will expand and strengthen to serve our customers’ growing clinical development needs in the fast-growing Chinese healthcare market,” comments Ge Li, Ph.D., chairman and CEO.

    WuXi is a pharma, biotech, and medical device R&D outsourcing specialist with operations in China and the U.S. Just 10 days ago it reported acquiring antibody and peptide reagents firm Abgent, including the latter’s facilities in China and San Diego.  

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »